

Amendments to the Claims

1. (Currently amended) An isolated antibody that binds to a conformational epitope of a Hepatitis C virus E2 protein, wherein the epitope is found in Hepatitis C virus of more than one genotype, and wherein the antibody is selected from the group consisting of CBH-2, CBH-4G, CBH-5, CBH-7, CBH-8C, and CBH-11, or binds to the same conformational epitope as that bound by an antibody selected from the group consisting of CBH-2, CBH-4G, CBH-5, CBH-7, CBH-8C, and CBH-11.
8. (Currently amended) An isolated antibody that binds to a conformational epitope within amino acids 411 through 644 of E2 protein of Hepatitis C virus 1b, wherein the antibody binds to the E2 protein of Hepatitis C virus of more than one genotype, wherein the antibody is selected from the group consisting of CBH-2, CBH-5, CBH-8C, and CBH-11, or binds to the same conformational epitope as that bound by an antibody selected from the group consisting of CBH-2, CBH-5, CBH-8C, and CBH-11.
9. (Currently amended) An isolated antibody that binds to a conformational epitope within amino acids 470 through 644 of E2 protein of Hepatitis C virus 1b, wherein the antibody is capable of binding to the E2 protein of Hepatitis C virus of more than one genotype, wherein the antibody is CBH-4G or CBH-7, or binds to the same conformational epitope as that bound by CBH-4G or CBH-7.
12. (Currently amended) An isolated antibody that binds to the epitope recognized by CBH-2, -4D, -4B, -4G, -5, -7, -8C or -11.
14. (Currently amended) The isolated antibody of claim 1 wherein the antibody inhibits binding of HCV E2 protein to CD81.
15. (Currently amended) A cell line expressing the isolated antibody of claim 1.
16. (Previously presented) The cell line of claim 15 wherein the cell line is a B cell line.

17. (Previously presented) The cell line of claim 15 wherein the cell line is a human cell line.
18. (Previously presented) The cell line of claim 15 wherein the cell line is a mammalian cell line.
19. (Previously presented) The cell line of claim 15 wherein the cell line is a eukaryotic cell line.
20. (Previously presented) The cell line of claim 15 wherein the cell line is a hybridoma.
21. (Previously presented) The cell line of claim 15 wherein the cell line has been transformed with Epstein-Barr virus (EBV).
22. (Previously presented) The cell line of claim 15 wherein the cell line has been infected with a virus.
25. (Currently amended) The isolated antibody of claim 1, 8, 9, or 12, wherein the antibody is a monoclonal antibody.
26. (Currently amended) The isolated antibody of claim 1, 8, 9, or 12, wherein the antibody is a human antibody.
27. (Currently amended) The isolated antibody of claim 1, 8, 9, or 12, wherein the antibody is a humanized antibody.
28. (Currently amended) The isolated antibody of claim 1 wherein the antibody is a mammalian antibody.
92. (Currently amended) A combination of two or more isolated antibodies wherein at least two of the antibodies bind to different conformational epitopes of E2 protein of Hepatitis C virus of more than one genotype, wherein each antibody is selected from the group consisting of CBH-2,

CBH-4G, CBH-5, CBH-7, CBH-8C, and CBH-11, or binds to the same conformational epitope as that bound by an antibody selected from the group consisting of CBH-2, CBH-4G, CBH-5, CBH-7, CBH-8C, and CBH-11.

93. (Previously presented) The combination of claim 92, wherein the combination shows increased total binding of the combined antibodies to E2 protein of Hepatitis C virus compared to the binding shown by any of the antibodies individually.

95. (Previously presented) The combination of claim 92 comprising CBH-7 and CBH-4G.

97. (Previously presented) The combination of claim 92 comprising CBH-7 and CBH-17.

103. (Previously presented) The combination of claim 92 comprising CBH-7 and CBH-5.

104. (Previously presented) The combination of claim 92 comprising CBH-7 and CBH-2.

105. (Previously presented) The combination of claim 93, wherein each antibody in the combination binds to a different epitope.

106. (Currently amended) An isolated antibody that binds to a conformational epitope of Hepatitis C virus E2 protein, wherein the antibody is selected from the group consisting of CBH-4B and CBH-4D.

107. (Currently amended) A combination of two or more isolated antibodies, at least two of which bind to different conformational epitopes of E2 protein of Hepatitis C virus, wherein each antibody is selected from the group consisting of CBH-4B, CBH-4D, CBH-4G, and CBH-7.